Last reviewed · How we verify
Lidocaine per-embolization
Lidocaine per-embolization is a Local anesthetic Small molecule drug developed by University Health Network, Toronto. It is currently FDA-approved for Pain management during embolization procedures. Also known as: Local anesthetic, Amide-type anesthetic, Lidocaine hydrochloride, 00884154.
Lidocaine is a local anesthetic administered before embolization procedures to reduce pain and discomfort during the interventional radiological intervention.
Lidocaine per-embolization is a treatment that involves injecting lidocaine into a specific artery to block pain signals, and it has been studied as a potential treatment for conditions such as uterine leiomyomas and knee osteoarthritis. Lidocaine per-embolization works by blocking sodium channels, specifically the sodium channel alpha subunit, which are involved in the transmission of pain signals.
At a glance
| Generic name | Lidocaine per-embolization |
|---|---|
| Also known as | Local anesthetic, Amide-type anesthetic, Lidocaine hydrochloride, 00884154 |
| Sponsor | University Health Network, Toronto |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Interventional Radiology / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Lidocaine blocks sodium channels in nerve cell membranes, preventing depolarization and transmission of pain signals. When administered pre-embolization, it provides local anesthesia to reduce procedural pain during vascular embolization interventions. This approach allows for improved patient comfort and potentially better procedural tolerance during minimally invasive vascular procedures.
Approved indications
- Pain management during embolization procedures
Common side effects
- Local injection site reactions
- Transient numbness or paresthesia
- Allergic reaction (rare)
Key clinical trials
- Genicular Artery Embolization vs Nerve Ablation Intervention (GENI) for Knee Osteoarthritis (NA)
- Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine per-embolization CI brief — competitive landscape report
- Lidocaine per-embolization updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI
Frequently asked questions about Lidocaine per-embolization
What is Lidocaine per-embolization?
How does Lidocaine per-embolization work?
What is Lidocaine per-embolization used for?
Who makes Lidocaine per-embolization?
Is Lidocaine per-embolization also known as anything else?
What drug class is Lidocaine per-embolization in?
What development phase is Lidocaine per-embolization in?
What are the side effects of Lidocaine per-embolization?
What does Lidocaine per-embolization target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: University Health Network, Toronto — full pipeline
- Therapeutic area: All drugs in Interventional Radiology / Pain Management
- Indication: Drugs for Pain management during embolization procedures
- Also known as: Local anesthetic, Amide-type anesthetic, Lidocaine hydrochloride, 00884154
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing